
|Articles|November 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
MB07133 gets orphan drug status
MB07133 gets orphan drug status
Advertisement
SAN DIEGOMetabasis Therapeutics' MB07133 has received orphan drug status from FDA for the treatment of hepatocellular carcinoma. MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis.
Articles in this issue
about 18 years ago
MT103, BiTE antibody, enters phase II testing for ALLabout 18 years ago
Sides dig in as ESA policy debate heats upabout 18 years ago
Ixempra gets ok for resistant breast cancerabout 18 years ago
ASCO adds Oncotype DX to marker guidelineabout 18 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenabout 18 years ago
Accelerated approval for Tasignaabout 18 years ago
Oxidative stress inducer ups survival in advanced melanomaabout 18 years ago
FDA removes partial hold on Telcyta clinical developmentabout 18 years ago
Should all HER2+ pts receive adjuvant trastuzumab?about 18 years ago
R-CHOP is standard of care for advanced DLBCL patientsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Prophylaxis and Practical Implementation of the COPERNICUS Approach
2
Pirtobrutinib Monotherapy Earns Canadian Approval in Lymphoma/Leukemia Populations
3
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
4
FDA Receives NDA for Lirafugratinib in 2L FGR2-Mutated Cholangiocarcinoma
5


































